Several posts acknowledge the limitations of procalcitonin levels in predicting bacterial infections in CAR T-cell therapy patients, such as noting its moderate predictive ability (AUC of 0.62), while others mention that all patients experienced CRS regardless of PCT results. The tone remains clinical and objective, reflecting cautious interest and recognition of the challenges in applying PCT as a biomarker in this context.
AgreementNeither agree nor disagree
Posts are somewhat neutral, with some recognizing the study's findings but not strongly endorsing or criticizing them.
InterestModerate interest
Discussions indicate a mild interest, as users are curious but do not deeply explore the topic.
EngagementNeutral engagement
Comments show minimal in-depth analysis, mostly summarizing or echoing the article's main points.
ImpactModerate impact
The conversations suggest the publication’s influence is moderate, prompting some consideration but not widespread debate.
Abstract in brief
The study investigates whether serum procalcitonin (PCT) levels can help distinguish bacterial infections from cytokine release syndrome (CRS) in patients undergoing CAR T-cell therapy, finding that PCT within 48 hours of fever onset is significantly associated with confirmed bacterial infections.
Elevated PCT levels had limited predictive ability, with an area under the curve (AUC) of 0.62, suggesting moderate accuracy in identifying bacterial infections among these patients.
All patients experienced CRS regardless of PCT levels, and broad-spectrum antibiotics were prescribed for similar durations whether bacterial infection was confirmed or not, indicating challenges in relying on PCT alone for infection management in this context.]
Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients https://t.co/SPV6SJtNNK https://t.co/nf6eN3NINw
This study explores whether serum procalcitonin levels can differentiate bacterial infections from cytokine release syndrome in CAR T-cell therapy patients, noting that elevated PCT within 48 hours correlates moderately…
Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients https://t.co/SPV6SJtNNK https://t.co/nf6eN3NINw